SIGNALAI·Jun 4, 2026, 4:00 AMSignal75Short term

Can I Take Another Dose? Evaluating LLM Decision-Making Under Temporal Uncertainty in OTC Dosing QA

Source: arXiv cs.AI

Share
Can I Take Another Dose? Evaluating LLM Decision-Making Under Temporal Uncertainty in OTC Dosing QA

arXiv:2606.04262v1 Announce Type: cross Abstract: Large language models (LLMs) are increasingly used for everyday health questions, including whether a user can safely take another dose of an over-the-counter (OTC) medication. Yet this common safety-relevant setting remains underexplored in existing medical QA evaluations, where correct answers require tracking dose timing, computing rolling 24-hour intake, following product-label constraints, and handling incomplete medication histories. We introduce DOSEBENCH, a focused benchmark of 81 curated OTC dosing scenarios focused on adult acetaminop

Why this matters
Why now

The proliferation of LLMs into everyday advisory roles necessitates rigorous evaluation of their safety in sensitive domains like health, which is currently underexplored.

Why it’s important

Evaluating LLM decision-making in critical health scenarios directly impacts public safety and the trustworthiness of AI in sensitive applications.

What changes

This introduction of DOSEBENCH establishes a specific benchmark for evaluating LLMs' ability to handle temporal uncertainty and complex constraints in medical advice, revealing current limitations.

Winners
  • · AI Safety Researchers
  • · Healthcare Tech Companies focused on robust AI
  • · Pharmaceuticals
Losers
  • · LLM Developers overlooking safety protocols
  • · Consumers relying on unchecked AI health advice
Second-order effects
Direct

Identification of specific failure modes for LLMs in medical dosing will lead to targeted improvements in model architectures and training data.

Second

Increased regulatory scrutiny and development of certification standards for AI systems providing health advice, especially those with public-facing applications.

Third

Enhanced public confidence in AI-driven health tools will depend significantly on demonstrated reliability in safety-critical tasks, influencing broad adoption.

Editorial confidence: 90 / 100 · Structural impact: 55 / 100
Original report

This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.

Read at arXiv cs.AI
Tracked by The Continuum Brief · live intelligence network
Share
The Brief · Weekly Dispatch

Stay ahead of the systems reshaping markets.

By subscribing, you agree to receive updates from THE CONTINUUM BRIEF. You can unsubscribe at any time.